ClinicalTrials.gg
TerminatedNCT03253185Updated Apr 27, 2018

A Study of SC-007 in Subjects With Advanced Cancer

A Phase 1 interventional study of SC-007 in Colorectal Cancer (CRC) and Gastric Cancer, sponsored by AbbVie. Terminated at 7 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-27.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Benefit/Risk Imbalance

From the registry’s dates

  • Primary completion was Mar 2018, 8 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Colorectal Neoplasms by AbbVie — 4 open to participants now, 8 under way, 1 of them phase 3. Colorectal Neoplasms · AbbVie.

Enrollment
17th of 17
7 · median 101
Started
2017
with 3 others
Phase 1
11 of 17
1 open now
Registered
8th of 17
by date

Among the 17 studies in Colorectal Neoplasms by AbbVie, this one is the 17th largest by enrollment, is one of 4 that started in 2017, is one of 11 in phase 1, and was the 8th registered.

Colorectal Neoplasms

6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 17 studies in Colorectal Neoplasms by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Colorectal Neoplasms by AbbVie, or all of them as a file.
02

Study summary

This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC-007 and consists of Part A (dose regimen finding) in participants with CRC followed by Part A in participants with gastric cancer. Part B (dose expansion) will enroll participants into separate disease specific cohorts of CRC or gastric cancer.

03

Conditions studied

  • Colorectal Cancer (CRC)
  • Gastric Cancer

Keywords

  • Cancer
  • Advanced cancer
  • Esophagogastric junction (EGJ) cancers
  • Maximum tolerated dose (MTD)
  • Maximum Tolerated Dose
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed advanced or unresectable advanced colorectal cancer (CRC) or gastric cancer that is , refractory, or progressive after:
  • CRC: at least 2 prior systemic regimens in the metastatic setting, and as appropriate in patients whose tumors are microsatellite instability-high (MSI-H), pembrolizumab as well.
  • Gastric cancer (including gastric and EGJ cancers): at least 2 prior systemic regimens in adjuvant, advanced, or metastatic setting and, as appropriate, a human epidermal growth factor receptor 2 () targeted agent.
  • (ECOG) performance status of 0 or 1
  • Adequate hematologic, hepatic, and renal function.

Exclusion criteria

Exclusion Criteria:

  • Any significant medical condition that, in the opinion of the investigator or sponsor, may place the participant at undue risk from the study.
  • Has (ECG) abnormalities that make corrected (QTc) evaluation difficult.
  • Prior exposure to a pyrrolobenzodiazepine or indolinobenzodiazepine based drug.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    SC-007

    SC-007 intravenous (IV) (various doses and dose regimens)

    Drug: SC-007

Interventions

  • DrugSC-007

    intravenous

06

What researchers measure

Primary outcomes

  1. Number of participants with dose-limiting toxicities (DLTs)

    DLTs graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.

    Time frame: Minimum first cycle of dosing (Up to 21 days)

Secondary outcomes

  1. Clinical Benefit Rate (CBR)

    CBR is defined as the proportion of participants with an objective response or stable disease (CR+PR+SD).

    Time frame: Approximately 4 years

  2. Progression Free Survival (PFS)

    PFS time is defined as the time from the participant's first dose of study drug (Day 1) to either the participant's disease progression or death due to any cause.

    Time frame: Approximately 4 years

  3. Observed plasma concentrations at trough (Ctrough) of SC-007

    Observed plasma concentrations at trough of SC-007

    Time frame: Approximately 1 year

  4. Incidence of Anti-therapeutic Antibodies (ATAs) against SC-007

    Incidence of ATAs against SC-007

    Time frame: Approximately 4 years

  5. Overall Survival (OS)

    OS is defined as the time from the participant's first dose date to death due to any cause.

    Time frame: Approximately 4 years

  6. Terminal half life (T1/2) of SC-007

    Terminal half life of SC-007

    Time frame: Approximately 1 year

  7. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants with complete response or partial response (CR+PR)

    Time frame: Approximately 4 years

  8. Duration of Response (DOR)

    DOR is defined as the time from the participant's initial objective response (CR or PR) to study drug therapy, to disease progression or death due to any cause, whichever occurs first.

    Time frame: Approximately 4 years

  9. Time to Cmax (Tmax) of SC-007

    Time to Cmax of SC-007

    Time frame: Approximately 1 year

  10. Area under the plasma concentration-time curve within a dosing interval (AUC) of SC-007

    Area under the plasma concentration-time curve within a dosing interval of SC-007

    Time frame: Approximately 1 year

  11. QTcF Change from Baseline

    QT interval measurement corrected by Fridericia's formula (QTcF)

    Time frame: Up to 9 weeks based on 3 cycles of dosing (21-day cycles)

  12. Maximum observed serum concentration (Cmax) of SC-007

    Maximum observed serum concentration of SC-007

    Time frame: Approximately 1 year

07

Study locations

7 sites
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • Mayo Clinic
    Rochester, Minnesota 55905-0001, United States
  • Washington University-School of Medicine
    Saint Louis, Missouri 63110, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • Tennessee Oncology-Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • South Texas Accelerated Research Therapeutics
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Mar 2018, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2017
First posted
Aug 17, 2017
StartActual
Sep 13, 2017
Primary completionActual
Mar 20, 2018
CompletionActual
Apr 2, 2018
Last update
Apr 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03253185
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 17, 2017
Start date
Sep 13, 2017
Primary completion
Mar 20, 2018
Completion
Apr 2, 2018
Last update
Apr 27, 2018

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion